Showing 6 posts of 6 posts found.


Amgen showcases positive Phase III multiple myeloma drug at ASCO

June 7, 2016
Manufacturing and Production, Research and Development ASCO, Amgen, Kyprolis, dexamethasone, lenalidomide, multiple myeloma

Amgen (NASDAQ: AMGN) has presented data showing a statistically significant increase in progression-free survival and overall response rate in multiple …


Darzalex meets endpoint in late-stage multiple myeloma trial

May 19, 2016
Research and Development Genmab, Janssen, daratumumab, darzalex, dexamethasone, lenalidomide, phase 3, phase III, trial

Genmab has announced that positive results from a Phase III trial evaluating Darzalex (daratumumab), which is being developed in partnership …

Celgene logo

Celgene settles Revlimid patent dispute

December 23, 2015
Manufacturing and Production, Research and Development, Sales and Marketing Celgene, India, Natco, Revlimid, lenalidomide, patents

Celgene has settled its litigation with Natco Pharma, over the patents for Revlimid, opening the door to increased generic competition …

Scotland flag

Cancer and MS drugs approved in Scotland

December 9, 2015
Sales and Marketing Celgene, Copaxone, Novartis, SMC, Scottish Medicines Consortium, Tevaq, ceritinib, glatiramer acetate, lenalidomide, lung cancer, multiple myeloma, multiple sclerosis, revlimis, zykadia

The Scottish Medicines Consortium (SMC) has approved three new treatments for lung cancer, multiple sclerosis and multiple myeloma, from Novartis, …

Revlimid image

Celgene gets FDA licence extension for myeloma drug

February 19, 2015
Sales and Marketing Celgene, FDA, Revlimid, lenalidomide, myeloma

The FDA has given Celgene an extended licence for its multiple myeloma drug Revlimid (lenalidomid), to include people who are …


ASCO cancer conference opens

June 4, 2010
Research and Development ASCO, Cancer, lenalidomide, rituximab

One of the most important dates in the pharmaceutical industry’s calendar, the ASCO cancer conference begins today. The American Society …

Latest content